Shinji Kohsaka
YOU?
Author Swipe
View article: BET family BRD3 initiates DSB-induced chromatin remodeling with TIP60 to promote R-loop-mediated HR
BET family BRD3 initiates DSB-induced chromatin remodeling with TIP60 to promote R-loop-mediated HR Open
Mechanisms for genome stability in actively transcribed regions are essential for cellular homeostasis; however, these mechanisms are poorly understood. Herein, we identify the bromodomain and extraterminal domain (BET) family BRD3 as the …
View article: Figure 1 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Figure 1 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
RAS protein domain and distribution of RAS mutations. A, RAS proteins comprise a G-domain consisting of five α-helix structures and six β-sheet structures, followed by a hypervariable region (HVR; 166–189 aa). The G-domain co…
View article: Supplementary Table S3 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Table S3 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Primer sequences used for next-generation sequencing
View article: Supplementary Figure S6 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Figure S6 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Concordance of FFA scores between KRAS and corresponding HRAS/NRAS variants
View article: Supplementary Figure S1 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Figure S1 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Schema of the assays for the variant assessment
View article: Supplementary Table S6 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Table S6 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Raw data for Figure 3A
View article: Supplementary Table S2 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Table S2 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Primer sequences used for barcode amplification
View article: Supplementary Table S1 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Table S1 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
The barcode sequence of each variant clone
View article: Figure 3 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Figure 3 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Drug sensitivity of KRAS variants to BI-2865. A, 3T3 cells expressing KRAS variants were treated with the indicated concentrations of BI-2865 (a pan-KRAS inhibitor). The viability of cells treated with BI-2865 was meas…
View article: Supplementary Figure S2 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Figure S2 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
The frequency of oncogenic RAS mutations in cancer according to the C-CAT database
View article: Supplementary Table S4 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Table S4 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Prevalence of canonical KRAS variants at mutant allele level
View article: Supplementary Figure S4 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Figure S4 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Transforming activity of NRAS variants
View article: Supplementary Figure S8 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Figure S8 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Concordance in the sensitivity to pan-KRAS inhibitor assessed through the MANO method and PrestoBlue cell viability assay
View article: Supplementary Figure S9 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Figure S9 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Immunoblot analysis of KRAS variants in 3T3 cells treated with BI-2865
View article: Supplementary Figure S5 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Figure S5 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Transforming activity of NRAS variants
View article: Supplementary Figure S3 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Figure S3 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Transforming activity of KRAS variants
View article: Supplementary Table S5 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Table S5 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Details of the 298 variants
View article: Data from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Data from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
The RAS gene is frequently mutated in human cancers. Whereas the functional significance of frequent mutations is well established, the significance of rare mutations remains unknown. This study aimed to comprehensively investigate …
View article: Table 1 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Table 1 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Incidence of RAS mutations in cancer.
View article: Supplementary Table S7 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Table S7 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Details of the drug sensitivity assay
View article: Supplementary Figure S7 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Supplementary Figure S7 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Proliferative capacity of KRAS variants in the co-culture assay
View article: Figure 2 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Figure 2 from Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
Lollipop chart and transforming activity of RAS variants. A, The results of the FFA for each RAS isoform are shown in the lollipop chart. The circle color indicates FFA scores, and the frame color of the circles indicates mut…
View article: Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance
Functional Analysis of Rare <i>RAS</i> Variants of Unknown Significance Open
The RAS gene is frequently mutated in human cancers. Whereas the functional significance of frequent mutations is well established, the significance of rare mutations remains unknown. This study aimed to comprehensively investigate the fun…
View article: Discovery of Novel <scp><i>RASGRF2</i></scp> Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers
Discovery of Novel <span><i>RASGRF2</i></span> Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers Open
Lung adenocarcinomas (LUADs) in never‐smokers exhibit distinct molecular profiles from those of smokers, and their driver mutations are quite divergent. We aimed to evaluate the utility of RNA‐seq for the molecular profiling of LUAD in Jap…
View article: Clinical presentation and prognostic factors of eyelid sebaceous carcinoma
Clinical presentation and prognostic factors of eyelid sebaceous carcinoma Open
View article: Prognostic potential of fusion gene analysis using plasma cell-free RNA in malignant bone and soft tissue tumours
Prognostic potential of fusion gene analysis using plasma cell-free RNA in malignant bone and soft tissue tumours Open
The detection of specific fusion genes from cfRNAs shows potential for monitoring the progression of fusion-related sarcomas in the context of chemotherapy.
View article: Supplementary Figure 1 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
Supplementary Figure 1 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers Open
Synthesis and in vivo DMPK profile of zongertinib
View article: Supplementary Figure 7 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
Supplementary Figure 7 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers Open
In vivo tumor responses for zongertinib monotherapy or combinations.
View article: Supplementary Data Table 2 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
Supplementary Data Table 2 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers Open
PRISM screen raw data.
View article: Supplementary Figure 2 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
Supplementary Figure 2 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers Open
Graphical NMR spectra of zongertinib and BI-3999